News & Views | Published:

A new lease on life for dendritic cell vaccines?

Extending the life span of dendritic cells improves the potency of cancer vaccines.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Nestle, F.O., Banchereau, J. & Hart, D. Nat. Med. 7, 761–765 (2001).

  2. 2

    Park, D., Lapteva, N., Seethammagari, M., Slawin, K.M. & Spencer, D.M. Nat. Biotechnol. 24, 1581–1590 (2006).

  3. 3

    Banchereau, J. & Steinman, R.M. Nature 392, 245–252 (1998).

  4. 4

    Reis e Sousa, C. Nat. Rev. Immunol. 6, 476–483 (2006).

  5. 5

    Schadendorf, D. et al. Ann. Oncol. 17, 563–570 (2006).

  6. 6

    Small, E.J. et al. J. Clin. Oncol. 24, 3089–3094 (2006).

  7. 7

    Srivastava, P.K. Curr. Opin. Immunol. 18, 201–205 (2006).

  8. 8

    Josien, R. et al. J. Exp. Med. 191, 495–502 (2000).

  9. 9

    Lowy, D.R. & Schiller, J.T. J. Clin. Invest. 116, 1167–1173 (2006).

  10. 10

    Boon, T., Coulie, P.G., Van den Eynde, B.J. & van der Bruggen, P. Annu. Rev. Immunol. 24, 175–208 (2006).

  11. 11

    Peggs, K.S., Quezada, S.A., Korman, A.J. & Allison, J.P. Curr. Opin. Immunol. 18, 206–213 (2006).

  12. 12

    Pulendran, B. & Ahmed, R. Cell 124, 849–863 (2006).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Figure 1: Enhancing the clinical efficacy of dendritic cell–based tumor vaccines.

Katie Ris